John J Powers

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9000370/publications.pdf

Version: 2024-02-01

86	1,187	471061	395343
papers	citations	17	33
		h-index	g-index

88	88	88	1852
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Essential role of HDAC6 in the regulation of PDâ€L1 inÂmelanoma. Molecular Oncology, 2016, 10, 735-750.	2.1	125
2	Targeting histone deacetylase 6 mediates a dual antiâ€melanoma effect: Enhanced antitumor immunity and impaired cell proliferation. Molecular Oncology, 2015, 9, 1447-1457.	2.1	111
3	Histone deacetylase 11: A novel epigenetic regulator of myeloid derived suppressor cell expansion and function. Molecular Immunology, 2015, 63, 579-585.	1.0	98
4	TGF-Î²-mediated silencing of genomic organizer SATB1 promotes Tfh cell differentiation and formation of intra-tumoral tertiary lymphoid structures. Immunity, 2022, 55, 115-128.e9.	6.6	62
5	Overexpression of TCL1 activates the endoplasmic reticulum stress response: a novel mechanism of leukemic progression in mice. Blood, 2012, 120, 1027-1038.	0.6	60
6	T cells lacking HDAC11 have increased effector functions and mediate enhanced alloreactivity in a murine model. Blood, 2017, 130, 146-155.	0.6	54
7	Ovarian cancer immunogenicity is governed by a narrow subset of progenitor tissue-resident memory TÂcells. Cancer Cell, 2022, 40, 545-557.e13.	7.7	53
8	The dual PI3KÎ´/CK1Îµ inhibitor umbralisib exhibits unique immunomodulatory effects on CLL T cells. Blood Advances, 2020, 4, 3072-3084.	2.5	52
9	<scp>WT</scp>1 vaccination in <scp>AML</scp> and <scp>MDS</scp>: A pilot trial with synthetic analog peptides. American Journal of Hematology, 2015, 90, 602-607.	2.0	50
10	Essential role for histone deacetylase 11 (HDAC11) in neutrophil biology. Journal of Leukocyte Biology, 2017, 102, 475-486.	1.5	44
11	A phase I clinical trial of ruxolitinib in combination with nilotinib in chronic myeloid leukemia patients with molecular evidence of disease. Leukemia Research, 2018, 74, 89-96.	0.4	42
12	HDAC11 deficiency disrupts oncogene-induced hematopoiesis in myeloproliferative neoplasms. Blood, 2020, 135, 191-207.	0.6	40
13	Treatment of Chronic Lymphocytic Leukemia with a Hypomethylating Agent Induces Expression of NXF2, an Immunogenic Cancer Testis Antigen. Clinical Cancer Research, 2009, 15, 3406-3415.	3.2	38
14	A molecular and functional analysis of large granular lymphocyte expansions in patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors. Leukemia and Lymphoma, 2011, 52, 668-679.	0.6	33
15	Changes in Immunogenicity of Chronic Lymphocytic Leukemia Cells Mediated by Epigenetic Modifiers. Blood, 2008, 112, 4202-4202.	0.6	28
16	IgA-Dominated Humoral Immune Responses Govern Patients' Outcome in Endometrial Cancer. Cancer Research, 2022, 82, 859-871.	0.4	21
17	Restoring the functional immunogenicity of chronic lymphocytic leukemia using epigenetic modifiers. Leukemia Research, 2011, 35, 394-404.	0.4	17
18	Results of a phase II study of lenalidomide and rituximab for refractory/relapsed chronic lymphocytic leukemia. Leukemia Research, 2016, 47, 78-83.	0.4	17

#	Article	IF	Citations
19	Silencing of HDAC6 as a therapeutic target in chronic lymphocytic leukemia. Blood Advances, 2018, 2, 3012-3024.	2.5	16
20	Epigenetic repolarization of T lymphocytes from chronic lymphocytic leukemia patients using 5-aza-2â€²-deoxycytidine. Leukemia Research, 2011, 35, 1193-1199.	0.4	15
21	HDAC6 Inhibition Alleviates CLL-Induced T-Cell Dysfunction and Enhances Immune Checkpoint Blockade Efficacy in the Eμ-TCL1 Model. Frontiers in Immunology, 2020, 11, 590072.	2.2	14
22	Olfactory Receptor OR2H1 Is an Effective Target for CAR T Cells in Human Epithelial Tumors. Molecular Cancer Therapeutics, 2022, 21, 1184-1194.	1.9	12
23	Circumventing Immune Tolerance Through Epigenetic Modification. Current Pharmaceutical Design, 2010, 16, 268-276.	0.9	11
24	Histone Deacetylase 6 (HDAC6) As a Regulator of Immune Check-Point Molecules in Chronic Lymphocytic Leukemia (CLL). Blood, 2014, 124, 3311-3311.	0.6	11
25	The novel differentiation of human blood mononuclear cells into CD1a-negative dendritic cells is stimulated in the absence of exogenous cytokines by an extract prepared from pinecones. International Immunopharmacology, 2003, 3, 209-223.	1.7	10
26	Abstract 545: Differential regulation of human T-cells by TGR-1202, a novel PI3Kδ inhibitor. , 2016, , .		9
27	Functional Analysis of Histone Deacetylase 11 (HDAC11). Methods in Molecular Biology, 2016, 1436, 147-165.	0.4	8
28	Phase I trial of histone deacetylase inhibitor panobinostat in addition to glucocorticoids for primary therapy of acute graft-versus-host disease. Bone Marrow Transplantation, 2018, 53, 1434-1444.	1.3	8
29	Plasma cell dependence on histone/protein deacetylase 11 reveals a therapeutic target in multiple myeloma. JCI Insight, 2021, 6, .	2.3	8
30	Expression and Function of Histone Deacetylase 10 (HDAC10) in B Cell Malignancies. Methods in Molecular Biology, 2016, 1436, 129-145.	0.4	7
31	HDAC11 regulates expression of C/EBPβ and immunosuppressive molecules in myeloid-derived suppressor cells. Journal of Leukocyte Biology, 2021, 109, 891-900.	1.5	7
32	A phase 2 trial of the histone deacetylase inhibitor panobinostat for graft-versus-host disease prevention. Blood Advances, 2021, 5, 2740-2750.	2.5	6
33	Exposure to a mycovirus containing Aspergillus Flavus reproduces acute lymphoblastic leukemia cell surface and genetic markers in cells from patients in remission and not controls. Cancer Treatment and Research Communications, 2021, 26, 100279.	0.7	5
34	Combination of ACY1215, a Selective Histone Deacetylase 6 (HDAC6) Inhibitor with the Bruton Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, Represents a Novel Therapeutic Strategy in Mantle Cell Lymphoma (MCL). Blood, 2012, 120, 1660-1660.	0.6	5
35	Plasma of Acute Lymphoblastic Leukemia Patients React to the Culture of a Mycovirus Containing Aspergillus flavus. Journal of Pediatric Hematology/Oncology, 2020, 42, 350-358.	0.3	4
36	A Phase I Study of Ruxolitinib Plus Nilotinib in Chronic Phase CML Patients with Molecular Evidence of Disease. Blood, 2016, 128, 1892-1892.	0.6	4

#	Article	IF	Citations
37	Mothering: Moral Cultivation in Buddhist and Feminist Ethics. Philosophy East and West, 1994, 44, 1.	0.0	3
38	Phase II Study of Lenalidomide in Combination with Rituximab for Patients with CD5+/CD20+ Hematologic Malignancies Who Relapse or Progress After Rituximab. Interim Analysis.. Blood, 2009, 114, 2376-2376.	0.6	3
39	Modulation of T Cell Compartment in a Preclinical CLL Murine Model By a Selective PI3K Delta Inhibitor, TGR-1202. Blood, 2016, 128, 3236-3236.	0.6	3
40	Indian Buddhist concepts of normative and deviant bodies: can ancient sexual mores be reconciled with modern sensibilities?. Religion, 2019, 49, 735-744.	0.3	2
41	A Comprehensive Lymphocyte Analysis of Dasatinib Treated Chronic Myelogenous Leukemia Patients Reveals T-Cell Oligoclonality.. Blood, 2008, 112, 1114-1114.	0.6	2
42	Epigenetic Modulation of STAT3 by Histone Deacetylase 6 (HDAC6) Regulates IL-10 Gene Expression and Immune Tolerance Mediated by Antigen-Presenting Cells (APCs). Blood, 2011, 118, 519-519.	0.6	2
43	Gender and Virtue in Indian Buddhism. CrossCurrents, 2011, 61, 428-440.	0.0	1
44	Selective Targeting of Histone Deacetylase 11 Disables Metabolism of Myeloproliferative Neoplasms. Blood, 2019, 134, 474-474.	0.6	1
45	Conventional Real Time Quantitative Polymerase Chain Reaction Method Yields Similar Level of Sensitivity to Digital Droplet Polymerase Chain Reaction for Detection of BCR-ABL p210 Transcripts in Patients with Chronic Phase Chronic Myeloid Leukemia. Blood, 2019, 134, 3382-3382.	0.6	1
46	The Opposing Role of Histone Deacetylase 10 (HDAC10) and HDAC11 in Proliferation/Survival of Mantle Cell Lymphoma (MCL) and Chronic Lymphocytic Leukemia (CLL). Blood, 2011, 118, 1363-1363.	0.6	1
47	A Novel Role For Histone Deacetylase 11 (HDAC11) In Plasma Cell Differentation and Survival. Blood, 2013, 122, 1907-1907.	0.6	1
48	A Novel Role For Histone Deacetylase 11 (HDAC11) As a Regulator Of Neutrophil Function and Differentiation In Normal and Malignant Hematopoesis. Blood, 2013, 122, 2267-2267.	0.6	1
49	Histone Deacetylase 11 (HDAC11) As a Novel Transcriptional Regulator of C/EBP-Î², in Immature Myeloid Cell to Myeloid Derived Suppressor Cell Transition. Blood, 2014, 124, 225-225.	0.6	1
50	HDAC11 as a candidate therapeutic target in multiple myeloma.. Journal of Clinical Oncology, 2017, 35, 8029-8029.	0.8	1
51	A Phase I Pilot Study of Bystander Vaccine and Lenalidomide Immune Augmentation In Patients with Myelodysplastic Syndrome (MDS). Blood, 2010, 116, 2925-2925.	0.6	1
52	Enhanced Immunological Responses Following K562/GM-CSF/CD40L Vaccine Plus Lenalidomide in High-Risk Myelodysplastic Syndrome. Blood, 2011, 118, 1725-1725.	0.6	1
53	A Novel Role of Histone Deacetylase 11 (HDAC11) in Regulation of Myeloid-Derived Suppressor Cell (MDSC) Expansion. Blood, 2011, 118, 2439-2439.	0.6	1
54	Loss of HDAC11 Promotes Myeloid-Derived Suppressor Cells Inhibition of T Cell Function in a Murine Lymphoma Microenvironment. Blood, 2018, 132, 1105-1105.	0.6	1

#	Article	IF	Citations
55	Functional Analysis of HDAC11 in Plasma Cell Development and Multiple Myeloma Survival. Blood, 2018, 132, 3223-3223.	0.6	1
56	Treatment of Chronic Lymphocytic Leukemia with a Hypomethylating Agent Induces Expression of NXF2, An Immunogenic Cancer Testis Antigen. Blood, 2008, 112, 4207-4207.	0.6	0
57	Hypercalcemia Following Treatment with Lenalidomide in Chronic Lymphocytic Leukemia (CLL).. Blood, 2009, 114, 4413-4413.	0.6	0
58	Molecular Profiling of Cancer Testis Antigens in Chronic Lymphocytic Leukemia.. Blood, 2009, 114, 4701-4701.	0.6	0
59	Restoring the Functional Immunogenicity of Chronic Lymphocytic Leukemia Using Epigenetic Modifiers.. Blood, 2009, 114, 5116-5116.	0.6	0
60	Molecular and Functional Analysis of Large Granular Lymphocyte Expansions in Chronic Myelogenous Leukemia Patients Undergoing Tyrosine Kinase Inhibitor Therapy.. Blood, 2009, 114, 2204-2204.	0.6	0
61	Abstract 4771: Molecular, epigenetic, and phenotypic repolarization of human T lymphocytes using 5-aza-2â€²-deoxycytidine increases CD8 responsiveness and induces Th1 polarity. , 2010, , .		0
62	Correlative Analysis of T Cell Subpopulations and CD20 Expression In a Phase II Study of Lenalidomide In Combination with Rituximab In Patients with Relapsed or Refractory CLL/SLL. Blood, 2010, 116, 4630-4630.	0.6	0
63	Molecular, Epigenetic, and Phenotypic Repolarization of T Lymphocytes From Chronic Lymphocytic Leukemia Patients Using 5-Aza-2â€²-Deoxycytidine. Blood, 2010, 116, 4651-4651.	0.6	0
64	Abstract 5526: Epigenetic repolarization of T lymphocytes from chronic lymphocytic leukemia patients using 5-aza-2â€™-deoxycytidine. , 2011, , .		0
65	Tubastatin A, a Selective HDAC6 Inhibitor, Enhances Antigen-Presenting Cell (APC) Function and Restores the Responsiveness of Anergic CD4+ T Cells. Blood, 2011, 118, 520-520.	0.6	0
66	Abstract 3555: Histone deacetylase 6 as a novel regulator of the immunogenicity and aggressiveness of melanoma. , 2012, , .		0
67	Abstract 3554: The histone deacetylase inhibitor LBH589 augments anti-tumor immunity through direct effects on tumor and immune cells leading to impaired tumor progressionin vivo. , 2012, , .		0
68	Abstract 4260: Histone deacetylase 11 (HDAC11) as a novel therapeutic target in the regulation of myeloid-derived suppressor cell (MDSC). , 2012, , .		0
69	Novel Role of Histone Deacetylase 11 (HDAC11) in Hematopoiesis. Blood, 2012, 120, 4728-4728.	0.6	0
70	Inducible Expression of Cancer Testis Antigens in Myelodysplastic Syndrome (MDS) Patients Following Treatment with an Oral 5-Azacytidine. Blood, 2012, 120, 3828-3828.	0.6	0
71	Physical Interaction of Histone Deacetylase 6 (HDAC6) with STAT3 Regulates IL-10 Gene Expression and Immune Tolerance Mediated by Antigen-Presenting Cells (APCs). Blood, 2012, 120, 829-829.	0.6	0
72	Histone Deacetylase 11 (HDAC11) Regulates Cytotoxic T-Cell Function and Memory Phenotype. Blood, 2012, 120, 840-840.	0.6	0

#	Article	IF	Citations
73	Abstract 692: Histone deacetylase 11 is an epigenetic regulator of CD8+ T-cell effector function and memory formation.. , 2013, , .		0
74	Histone Deacetylase 11 (HDAC11) Is a Novel Regulator In The Expansion Of MDSCs Via The Transcription Factor C/EBP-Î². Blood, 2013, 122, 4887-4887.	0.6	0
75	Abstract 5537: Histone deacetylase 11 (HDAC11) regulates B cell lymphopoiesis and potentiates plasma cell survival in multiple myeloma. , 2014, , .		0
76	Abstract 4090: Inhibition of class I histone deacetylases promotes robust and durable enhancement of PDL1 expression in melanoma: Rationale for combination therapy. , 2014, , .		0
77	A Novel Role for Histone Deacetylase 11 (HDAC11) in B Cell Lymphopoiesis and Plasma Cell Survival in Multiple Myeloma. Blood, 2014, 124, 4715-4715.	0.6	0
78	Selective Inhibition of HDAC6 Decreases Viability of Cutaneous T-Cell Lymphoma and Improves Immune Recognition. Blood, 2014, 124, 5423-5423.	0.6	0
79	Abstract 2331: HDAC6, new role as master regulator of PD-L1 and immune-related pathways. , 2016, , .		0
80	Abstract 4485: Regulation of chronic lymphocytic leukemia (CLL) immunobiology by histone deacetylase 6 (HDAC6). , 2016, , .		0
81	Combinatorial Effect of HDAC6i and Ibrutinib Therapy in CLL Murine Model. Blood, 2016, 128, 2035-2035.	0.6	0
82	Abstract 4055: Enhancing anti-PD-1 immune blockade in melanoma through selective inhibition of histone deacetylase 6. , 2017, , .		0
83	Abstract 1703: The HDAC6 inhibitor Nexturastat A improvesin vivoPD-1 immune blockade. , 2018, , .		0
84	Abstract 4967: HDAC11 function as a transcriptional regulator in immature myeloid cells to myeloid-derived suppressor cells transition. , 2018, , .		0
85	Abstract 4723: Combinatorial efficacy of anti-PD1 treatment and selective histone deacetylase 6 (HDAC6) inhibition in chronic lymphocytic leukemia (CLL). , 2019, , .		0
86	Abstract LB-074: Priming the tumor microenvironment with epigenetic modifiers to overcome resistance to immune checkpoint inhibitors. , 2019, , .		0